Vimseltinib
CAS 1628606-05-2Small Molecule
Overview
Vimseltinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL5095202).
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Vimseltinib expires 30 Apr 2045 and exclusivity 14 Feb 2030. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- 3-methyl-5-[6-methyl-5-[[2-(1-methylpyrazol-4-yl)-4-pyridinyl]oxy]-2-pyridinyl]-2-(propan-2-ylamino)pyrimidin-4-one
- Canonical SMILES
- CC1=C(C=CC(=N1)C2=CN=C(N(C2=O)C)NC(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C
- InChIKey
- TVGAHWWPABTBCX-UHFFFAOYSA-N
Verified Supplier Partner
Do you supply Vimseltinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.